216 related articles for article (PubMed ID: 9600249)
1. Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users.
Alvarez V; López-Larrea C; Coto E
Hum Genet; 1998 Apr; 102(4):483-6. PubMed ID: 9600249
[TBL] [Abstract][Full Text] [Related]
2. Frequency of the CCR5 delta 32 mutant allele in HIV-1-positive patients, female sex workers, and a normal population in Taiwan.
Li C; Yan YP; Shieh B; Lee CM; Lin RY; Chen YM
J Formos Med Assoc; 1997 Dec; 96(12):979-84. PubMed ID: 9444918
[TBL] [Abstract][Full Text] [Related]
3. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort.
Eugen-Olsen J; Iversen AK; Benfield TL; Koppelhus U; Garred P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):110-6. PubMed ID: 9637575
[TBL] [Abstract][Full Text] [Related]
5. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.
Smith MW; Dean M; Carrington M; Winkler C; Huttley GA; Lomb DA; Goedert JJ; O'Brien TR; Jacobson LP; Kaslow R; Buchbinder S; Vittinghoff E; Vlahov D; Hoots K; Hilgartner MW; O'Brien SJ
Science; 1997 Aug; 277(5328):959-65. PubMed ID: 9252328
[TBL] [Abstract][Full Text] [Related]
6. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.
Quillent C; Oberlin E; Braun J; Rousset D; Gonzalez-Canali G; Métais P; Montagnier L; Virelizier JL; Arenzana-Seisdedos F; Beretta A
Lancet; 1998 Jan; 351(9095):14-8. PubMed ID: 9433423
[TBL] [Abstract][Full Text] [Related]
7. CCR5 genotypes and progression to HIV disease in perinatally infected children.
de Angelis DS; Freire WS; Pannuti CS; Succi RC; Machado DM
Braz J Infect Dis; 2007 Apr; 11(2):196-8. PubMed ID: 17625759
[TBL] [Abstract][Full Text] [Related]
8. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population.
Apostolakis S; Baritaki S; Krambovitis E; Spandidos DA
J Clin Virol; 2005 Dec; 34(4):310-4. PubMed ID: 16286055
[TBL] [Abstract][Full Text] [Related]
9. The first report of CCR5 delta 32 mutant in Thai injecting drug users.
Ruchusatsawat N; Vongsheree S; Thaisri H; Phutiprawan T
Asian Pac J Allergy Immunol; 2000 Jun; 18(2):93-8. PubMed ID: 10928621
[TBL] [Abstract][Full Text] [Related]
10. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users.
Barber Y; Rubio C; Fernández E; Rubio M; Fibla J
J Infect Dis; 2001 Nov; 184(10):1279-88. PubMed ID: 11679916
[TBL] [Abstract][Full Text] [Related]
11. [The HIV-infection outbreak in the town Lys'va (Perm region): homozygote genotype CCR5 delta32/CCR5 delta32 provides the high level of the persistence in the parenteral transmission of the virus].
Riabov GS; Kazennova EV; Korepanova LB; Mal'tseva EA; Zhalnin VV; Krasnikova LA; Zverev SIa; Pokrovskiĭ VV; Bobkov AF; Weber JN
Vopr Virusol; 2002; 47(4):13-6. PubMed ID: 12271718
[TBL] [Abstract][Full Text] [Related]
12. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
Li H; Liu TJ; Hong ZH
Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
[TBL] [Abstract][Full Text] [Related]
13. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
[TBL] [Abstract][Full Text] [Related]
14. A SDF1 genetic variant confers resistance to HIV-1 infection in intravenous drug users in China.
Gong X; Liu Y; Liu FL; Jin L; Wang H; Zheng YT
Infect Genet Evol; 2015 Aug; 34():137-42. PubMed ID: 26168882
[TBL] [Abstract][Full Text] [Related]
15. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe.
Libert F; Cochaux P; Beckman G; Samson M; Aksenova M; Cao A; Czeizel A; Claustres M; de la Rúa C; Ferrari M; Ferrec C; Glover G; Grinde B; Güran S; Kucinskas V; Lavinha J; Mercier B; Ogur G; Peltonen L; Rosatelli C; Schwartz M; Spitsyn V; Timar L; Beckman L; Parmentier M; Vassart G
Hum Mol Genet; 1998 Mar; 7(3):399-406. PubMed ID: 9466996
[TBL] [Abstract][Full Text] [Related]
16. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM
AIDS; 1997 Dec; 11(15):1833-8. PubMed ID: 9412701
[TBL] [Abstract][Full Text] [Related]
17. Distribution of CCR5 genotypes and HLA Class I B alleles in HIV-1 infected and uninfected injecting drug users from Rio de Janeiro, Brazil.
Teixeira SL; Bastos FI; Hacker MA; Morgado MG
Infect Genet Evol; 2009 Jul; 9(4):638-42. PubMed ID: 19460331
[TBL] [Abstract][Full Text] [Related]
18. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group.
Clegg AO; Ashton LJ; Biti RA; Badhwar P; Williamson P; Kaldor JM; Stewart GJ
AIDS; 2000 Jan; 14(2):103-8. PubMed ID: 10708279
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.
Morawetz RA; Rizzardi GP; Glauser D; Rutschmann O; Hirschel B; Perrin L; Opravil M; Flepp M; von Overbeck J; Glauser MP; Ghezzi S; Vicenzi E; Poli G; Lazzarin A; Pantaleo G
Eur J Immunol; 1997 Dec; 27(12):3223-7. PubMed ID: 9464809
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 polymorphisms and HIV-1 pathogenesis.
Martin MP; Carrington M; Dean M; O'Brien SJ; Sheppard HW; Wegner SA; Michael NL
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):430. PubMed ID: 9833755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
